设计抗松体和抗莱什曼体的体型衍生物:一个计算和体外评估
Raquel C R Gonçalves1,2, Filipe Teixeira1, Pablo Peñalver3
1Centre of Chemistry, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal.
Molecules (Basel, Switzerland)
|May 11, 2024
概括
新的BODIPY衍生品显示出对抗寄生虫疾病的承诺,如莱什曼病和非洲试虫病. 这些化合物向必要的酶,在当前选择有限的情况下提供潜在的新疗法.
科学领域:
- 药用化学 医学化学
- 寄生虫学的寄生虫学
- 生物化学 生化学
背景情况:
- 在资源有限的地区,莱什曼病和人类非洲试虫病是主要的健康问题.
- 目前对这些原生动物疾病的治疗方法有局限性,并且没有疫苗可用.
- 对于新型治疗药物有着至关重要的需求.
研究的目的:
- 为了合成和描述新的BODIPY衍生品.
- 为了评估这些化合物的体外活性对 *Trypanosoma brucei* 和 *Leishmania major* 寄生虫.
- 评估这些化合物对人类细胞的选择性.
主要方法:
- 功能化的BODIPY衍生品的合成和表征.
- 在体外抗寄生虫活性测定对 *T. brucei* 和 *L. major*.
- 使用MRC-5人类细胞系进行细胞毒性测定.
- 分子对接研究以阐明作用机制.
主要成果:
- 介质替代的BODIPYs (1b,1c) 对*L.大*具有很好的选择性,并且高度活跃.
- 单甲基化类似物 (2b,2c) 显示出对 *T. brucei* 的强烈活性和选择性.
- 分子对接表明通过向NADPH/NADP+结合部位来竞争性抑制丁氨酸减少酶 (PR).
结论:
- BODIPY衍生品显示出对被忽视的热带疾病具有显著的抗寄生虫潜力.
- 这些化合物作为丁氨酸减少酶的竞争性抑制剂,提供了一种新的治疗策略.
- 这些发现表明,抗寄生虫活性和酶结合配置之间存在相关性.
更多相关视频
08:48Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation
Published on: January 26, 2016
11.8K
12:02An Efficient Method for the Synthesis of Peptoids with Mixed Lysine-type/Arginine-type Monomers and Evaluation of Their Anti-leishmanial Activity
Published on: November 2, 2016
12.1K
相关概念视频
01:15Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...